Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more) This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

CalciMedica Inc CALC

Healthcare Biotechnology
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.


NDAQ:CALC - Post by User

CalciMedica Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
  • PronorvistaX
Post by Pronorvistaon Feb 03, 2023 11:03am
383 Views
Post# 35264817

GRAY

GRAYVery good results last drilling.

Graycliff drills three m of 14.39 g/t Au at Shakespeare
2022-10-06 12:20 C:GRAY Graycliff Exploration Ltd 0.10 News Release Graycliff drills six m of 10.09 g/t Au at Shakespeare
2022-09-28 11:21 C:GRAY Graycliff Exploration Ltd 0.11 News Release Graycliff drills nine m of 10.93 g/t Au at Shakespeare

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities